Thompson Davis & CO. Inc. Has $471,000 Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Thompson Davis & CO. Inc. decreased its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 15.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,100 shares of the company’s stock after selling 2,725 shares during the quarter. Thompson Davis & CO. Inc.’s holdings in CareDx were worth $471,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in CareDx by 1,021.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock valued at $34,000 after acquiring an additional 2,013 shares in the last quarter. Plato Investment Management Ltd acquired a new stake in shares of CareDx during the second quarter worth approximately $62,000. KBC Group NV purchased a new position in CareDx during the third quarter valued at approximately $99,000. nVerses Capital LLC increased its stake in CareDx by 175.0% in the 3rd quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock valued at $103,000 after buying an additional 2,100 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in CareDx in the 2nd quarter valued at approximately $142,000.

CareDx Price Performance

NASDAQ CDNA opened at $22.06 on Wednesday. The firm has a market cap of $1.18 billion, a P/E ratio of -8.17 and a beta of 1.80. The stock’s 50-day moving average is $26.56 and its two-hundred day moving average is $21.88. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The business had revenue of $82.88 million for the quarter, compared to the consensus estimate of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm’s revenue was up 23.4% compared to the same quarter last year. During the same period last year, the business earned ($0.43) EPS. On average, equities analysts expect that CareDx, Inc will post -0.7 EPS for the current year.

Wall Street Analysts Forecast Growth

CDNA has been the topic of several research analyst reports. HC Wainwright restated a “neutral” rating on shares of CareDx in a report on Tuesday, October 22nd. The Goldman Sachs Group lifted their price objective on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Wells Fargo & Company assumed coverage on CareDx in a research report on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 target price on the stock. BTIG Research cut their price target on CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, November 5th. Finally, Craig Hallum boosted their price target on CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.60.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.